Search Knowledge Base

8 results for "bevacizumab"

Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial. unknown
wiki/source/pmid-36739879
A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial. unknown
wiki/source/pmid-38059497
A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer. unknown
wiki/source/pmid-41482380
A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab unknown
wiki/sources/nct-nct02673710
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial. unknown
wiki/sources/pmid-36739879
A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial. unknown
wiki/sources/pmid-38059497
A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer. unknown
wiki/sources/pmid-41482380
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery pubmed_article
Evidence Source 2018 PMID: 29987845

Evidence Search Results semantic · quality-ranked

Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial. rct pubmed_article
Quality: 53 PMID: 36739879 DOI: 10.1016/S1470-2045(23)00001-3
Direct oral anticoagulants in patients with atrial fibrillation and bioprosthetic valve replacement: A meta-analysis meta_analysis pubmed_article
Quality: 63 2021 PMID: 34383369 DOI: 10.1002/ccd.29911
Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis meta_analysis pubmed_article
Quality: 55 2023 PMID: 37419006 DOI: 10.1016/j.thromres.2023.06.027
Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment meta_analysis pubmed_article
Quality: 74 2012 PMID: 22895926 DOI: 10.1002/14651858.CD002071.pub3
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation meta_analysis pubmed_article
Quality: 72 2017 PMID: 29285754 DOI: 10.1002/14651858.CD006466.pub6
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation systematic_review pubmed_article
Quality: 57 2021 PMID: 34622445 DOI: 10.1002/14651858.CD006466.pub7
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis meta_analysis pubmed_article
Quality: 60 2018 PMID: 28950374 DOI: 10.1093/ehjcvp/pvx028
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation meta_analysis pubmed_article
Quality: 74 2014 PMID: 24677203 DOI: 10.1002/14651858.CD009893.pub2
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement meta_analysis pubmed_article
Quality: 73 2010 PMID: 20393944 DOI: 10.1002/14651858.CD005981.pub2
Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation meta_analysis pubmed_article
Quality: 62 2014 PMID: 24980743 DOI: 10.1002/14651858.CD006466.pub5

View full evidence search →